Venlafaxine
- Generic Name
- Venlafaxine
- Brand Names
- Effexor
- Drug Type
- Small Molecule
- Chemical Formula
- C17H27NO2
- CAS Number
- 93413-69-5
- Unique Ingredient Identifier
- GRZ5RCB1QG
- Background
Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, desvenlafaxine, works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD...
- Indication
Venlafaxine is indicated for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder.
- Associated Conditions
- Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Migraine, Neuropathic Pain, Panic Disorder, Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause
- Associated Therapies
- -
Pharmacogenomics Studies of Antidepressants
- Conditions
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT01204086
- Locations
- 🇨🇳
National Cheng-Kung University Hospital, Tainan, Taiwan
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 311
- Registration Number
- NCT01011751
- Locations
- 🇫🇷
Professor Jacques IRANI, Poitiers, France
Venlafaxine and Hypnosis or Focused Attention In Treating Patients With Hot Flashes
- Conditions
- Interventions
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT01000623
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Comparison of the Pharmacokinetics of Two Generic Antidepressants and Their Respective Brand Preparations
- Conditions
- Interventions
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2009-02-11
- Lead Sponsor
- University of Ottawa
- Target Recruit Count
- 18
- Registration Number
- NCT00676039
- Locations
- 🇨🇦
University of Ottawa, Institute of Mental Health Research, Ottawa, Ontario, Canada
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 85
- Registration Number
- NCT00667121
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Antidepressant Therapy for Bipolar II Major Depression
- Conditions
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2008-03-24
- Lead Sponsor
- Stanley Medical Research Institute
- Target Recruit Count
- 90
- Registration Number
- NCT00641927
- Locations
- 🇺🇸
Depression Research Unit, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study of the Effects of an Antidepressant Medication and Placebo on the Brain Functioning of Normal Subjects
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 6
- Registration Number
- NCT00634283
- Locations
- 🇺🇸
University of California Los Angeles (UCLA), Los Angeles, California, United States
Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression
- Conditions
- Interventions
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Örebro County Council
- Target Recruit Count
- 56
- Registration Number
- NCT00627887
- Locations
- 🇸🇪
Psychiatric clinic, Orebro, Sweden
🇸🇪Psychiatric Clinic, Uppsala, Sweden
🇸🇪Löwenströmska sjukhuset, Stockholm, Sweden
A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 18
- Registration Number
- NCT00611676
Antidepressant Therapy in Treating Bipolar Type II Major Depression
- Conditions
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 140
- Registration Number
- NCT00602537
- Locations
- 🇺🇸
Depression Research Unit - University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.